Last updated on September 2017

Trial of Adcetris in CD30+ Malignant Mesothelioma


Brief description of study

The goal of this clinical research study is to learn if Adcetris (brentuximab vedotin) can help to control mesothelioma. The safety of this drug will also be studied.

Detailed Study Description

Study Drug Administration: There are 21 days (about 3 weeks) in each study cycle. If you are found to be eligible to take part in this study, you will receive brentuximab vedotin by vein over about 30 minutes on Day 1 of every cycle. Length of Study: You may continue taking the study drug for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. Your participation on this study will be over after you have completed follow-up (described below). Study Visits: On Day 1 of every cycle: - You will have a physical exam - Blood (about 4 teaspoons) will be drawn for routine tests Every 6 weeks while you are on study, you will have a PET-CT scan to check the status of the disease. Follow-Up: The study doctor or study team will follow you up with you about 30 days after your last dose of brentuximab vedotin by either reviewing your medical record or calling you to learn if you have had any side effects. You will continue to have these follow-ups at 3 months, 6 months, and then every 6 months after that while you are on study. This is an investigational study. Brentuximab vedotin is FDA approved and commercially available for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. It is considered investigational to use brentuximab vedotin in patients with mesothelioma. The study doctor can explain how the study drug is designed to work. Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.

Clinical Study Identifier: NCT03007030

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Clinical Research Operations

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »